Using a new imaging probe to identify non-muscle-invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with suspected non-muscle-invasive bladder cancer (NMIBC) who are scheduled for surgical intervention. After surgery, excised tissues will be treated with a Trop2-targeting near-infrared (NIR-II) molecular probe to enhance visualization of cancerous tissues. The study aims to correlate the fluorescence imaging results with pathological diagnoses to improve detection and management of NMIBC. The methodology includes specific incubation procedures and advanced imaging techniques to capture detailed information about the tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients between 18-80 years of age
* Patients with suspected bladder cancer scheduled to undergo surgical intervention.
* Good operative candidate
* Subject capable of giving informed consent and participating in the process of consent

Exclusion Criteria:

* Patients unable to participate in the consent process
* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
* Other conditions that the researcher considers inappropriate to participate in the study

Where it's running

• Yunnan Cancer Hospital
  Kunming, Yunnan, China Recruiting

Study contacts

• Study coordinator: Shengjie Lin, Doctor of Medicine
• Email: linshengjie1128@163.com
• Phone: 86+18359010705

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Trop2-targeted NIR-II probe to identify bladder cancer in ex vivo samples

  A phase 2 study tests whether a Trop2-targeted NIR-II fluorescent probe can highlight bladder cancer lesions on ex vivo bladder tissue from patients undergoing radical cystectomy.

  Recruiting Phase 2 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07848854

• Non-invasive urine test to screen for urothelial cancer in adults with blood in urine

  A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.

  Recruiting Henan Provincial People's Hospital · Zhengzhou, Henan · NCT07614594

• Local radiotherapy for bladder cancer in patients not eligible for curative treatment

  This trial tests whether adding local hypofractionated adaptive radiotherapy to standard care can improve survival and reduce symptoms for bladder cancer patients who aren’t candidates for curative treatment.

  Recruiting Umeå University · Umeå, Västerbotten County · NCT07524426

• KD01 delivered directly into the bladder for bladder cancer

  This Phase I test gives KD01—an oncolytic adenovirus—directly into the bladder to see if it is safe and shows early benefit for adults with high‑risk non‑muscle‑invasive disease or certain muscle‑invasive bladder cancers.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07359235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.